Fulcrum therapeutics announces pricing of public offering of common stock

Cambridge, mass., aug. 15, 2022 (globe newswire) -- fulcrum therapeutics, inc. ® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,590,792 shares of its common stock at a public offering price of $7.82 per share. the gross proceeds to fulcrum from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be $75 million. all shares in the offering are to be sold by fulcrum. in addition, fulcrum has granted the underwriters a 30-day option to purchase up to an additional 1,438,618 shares of its common stock. the offering is expected to close on or about august 18, 2022, subject to customary closing conditions.
FULC Ratings Summary
FULC Quant Ranking